RENOVA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Renova, and when can generic versions of Renova launch?
Renova is a drug marketed by Valeant Pharms North and is included in two NDAs.
The generic ingredient in RENOVA is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the tretinoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Renova
A generic version of RENOVA was approved as tretinoin by PADAGIS US on December 24th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RENOVA?
- What are the global sales for RENOVA?
- What is Average Wholesale Price for RENOVA?
Summary for RENOVA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 140 |
| Clinical Trials: | 5 |
| Drug Prices: | Drug price information for RENOVA |
| What excipients (inactive ingredients) are in RENOVA? | RENOVA excipients list |
| DailyMed Link: | RENOVA at DailyMed |
Recent Clinical Trials for RENOVA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dwight Owen | Phase 1 |
| Prospect Creek Foundation | Phase 1 |
| Oregon Health and Science University | Phase 1 |
Pharmacology for RENOVA
| Drug Class | Retinoid |
US Patents and Regulatory Information for RENOVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharms North | RENOVA | tretinoin | CREAM;TOPICAL | 021108-001 | Aug 31, 2000 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Valeant Pharms North | RENOVA | tretinoin | CREAM;TOPICAL | 019963-001 | Dec 29, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RENOVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Valeant Pharms North | RENOVA | tretinoin | CREAM;TOPICAL | 021108-001 | Aug 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Valeant Pharms North | RENOVA | tretinoin | CREAM;TOPICAL | 019963-001 | Dec 29, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Valeant Pharms North | RENOVA | tretinoin | CREAM;TOPICAL | 019963-001 | Dec 29, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RENOVA
See the table below for patents covering RENOVA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 140388 | ⤷ Sign Up | |
| Canada | 1324962 | COMPOSITIONS ET METHODES POUR RETARDER LES EFFETS DU VIEILLISSEMENT DE LA PEAU (COMPOSITIONS AND METHODS FOR RETARDING THE EFFECTS OF AGING OF THE SKIN) | ⤷ Sign Up |
| Germany | 3562543 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RENOVA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0617614 | 2001/009 | Ireland | ⤷ Sign Up | PRODUCT NAME: PANRETIN-ALITRETINOIN |
| 1304992 | 2013/044 | Ireland | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322 |
| 1304992 | 92401 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
